Back to search results

AMB-05X for Colorectal Cancer with Detectable ctDNA

This study is testing a drug called AMB-05X for people with colorectal cancer. You might be able to join if you have already finished treatments meant to cure your cancer, but a special blood test (ctDNA(+)) still shows signs of cancer cells, even if scans don't. The main goal is to see how safe AMB-05X is and if it can clear these cancer cell signs from your blood after 6 months. The study plans to include about 15 participants and is currently looking for people to join.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It aims to enroll 15 participants.
What's involved
You would receive AMB-05X through an IV. Safety and side effects will be monitored throughout the study, which is expected to last an average of 1 year.
Compensation
Not stated in the trial record.
Follow-up
The study will track safety and side effects through study completion, an average of 1 year. It will also estimate 2-year disease-free survival and overall survival.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06617858

Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment

Recruiting
PHASE2Ages 18+InterventionalTreatment
M.D. Anderson Cancer Center
~15 participants
Updated 2026-08-25 on ClinicalTrials.gov
What's tested:AMB-05X

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and Adverse Events (AEs)
Measured over Through study completion; an average of 1 year.

Conditions

Colorectal Cancer

Explore related trials

Colorectal CarcinomaCirculating Tumor-Derived DNA Negative

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Van Morris, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Van Morris, MD
[email protected]
(713) 792-2828
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Postmenopausal (no menses in greater than or equal to 12 consecutive months).
History of hysterectomy or bilateral salpingo-oophorectomy.
Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).
History of bilateral tubal ligation or another surgical sterilization procedure. 10. Approved methods of birth control are as follows: Hormonal contraception (i.e., birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. 11. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 90 days after completion of AMB-05X administration.

What this trial measures

  • Safety and Adverse Events (AEs)Through study completion; an average of 1 year.

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0